Minerva Neurosciences (NERV) EPS (Weighted Average and Diluted) (2019 - 2026)
Minerva Neurosciences (NERV) reported EPS (Weighted Average and Diluted) of -$2.86 for Q1 2026, down 472.0% on a YoY basis from $0.77 in Q1 2025, and up 91.43% quarter-over-quarter from -$33.38 in Q4 2025.
Minerva Neurosciences (NERV) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Minerva Neurosciences has reported EPS (Weighted Average and Diluted) for 8 years, with the latest figure at -$2.86 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 472.0% year-over-year to -$2.86; the trailing twelve-month figure through Mar 2026 stood at -$37.03 (down 4615.85% YoY), and the FY2025 full-year result was -$34.67, down 18347.37% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$2.86, up from -$33.38 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $2.97 in Q3 2024, with the low at -$33.38 in Q4 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$2.82 across 5 years, with a median of -$1.13 in 2024.
- Annual changes were most pronounced in 2024 — EPS (Weighted Average and Diluted) surged 388.35% — and 2025, when it slumped 5860.71%.
- Minerva Neurosciences' EPS (Weighted Average and Diluted) stood at -$1.26 in 2022, then grew by 4.76% to -$1.2 in 2023, then surged by 53.33% to -$0.56 in 2024, then tumbled by 5860.71% to -$33.38 in 2025, then jumped by 91.43% to -$2.86 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$2.86 (Q1 2026), -$33.38 (Q4 2025), and -$0.36 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Minerva Neurosciences | 197.55 Mn | 197.55 Mn | - | -2.86 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.86 |
| Dec 31, 2025 | -33.38 |
| Sep 30, 2025 | -0.36 |
| Jun 30, 2025 | -0.43 |
| Mar 31, 2025 | -0.50 |
| Dec 31, 2024 | -0.56 |
| Sep 30, 2024 | 2.97 |
| Jun 30, 2024 | -1.09 |
| Mar 31, 2024 | -1.13 |
| Dec 31, 2023 | -1.20 |
| Sep 30, 2023 | -1.03 |
| Jun 30, 2023 | -1.12 |
| Mar 31, 2023 | -1.31 |
| Dec 31, 2022 | -1.26 |
| Sep 30, 2022 | -1.29 |
| Jun 30, 2022 | -1.63 |
| Mar 31, 2022 | -1.83 |
| Dec 31, 2021 | -3.99 |
| Sep 30, 2021 | -1.72 |
| Jun 30, 2021 | -0.25 |